An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E., Middleton, M. R., Friedlander, M., Gourley, C., Plummer, R., Rustin, G., Sessa, C., Leunen, K., Ledermann, J., Swaisland, H., Fielding, A., Bannister, W., Nicum, S., Molife, L. R.
Published in Targeted oncology (01.06.2016)
Published in Targeted oncology (01.06.2016)
Get full text
Journal Article
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
Olmos, D., Arkenau, H.-T., Ang, J.E., Ledaki, I., Attard, G., Carden, C.P., Reid, A.H.M., A'Hern, R., Fong, P.C., Oomen, N.B., Molife, R., Dearnaley, D., Parker, C., Terstappen, L.W.M.M., de Bono, J.S.
Published in Annals of oncology (01.01.2009)
Published in Annals of oncology (01.01.2009)
Get full text
Journal Article
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
Molife, L. R., Attard, G., Fong, P. C., Karavasilis, V., Reid, A. H. M., Patterson, S., Riggs, C. E., Higano, C., Stadler, W. M., McCulloch, W., Dearnaley, D., Parker, C., de Bono, J. S.
Published in Annals of oncology (01.01.2010)
Published in Annals of oncology (01.01.2010)
Get full text
Journal Article
A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and or paclitaxel in patients with solid tumours
Lassen, U, Molife, L R, Sorensen, M, Engelholm, S-A, Vidal, L, Sinha, R, Penson, R T, Buhl-Jensen, P, Crowley, E, Tjornelund, J, Knoblauch, P, de Bono, J S
Published in British journal of cancer (29.06.2010)
Published in British journal of cancer (29.06.2010)
Get full text
Journal Article
A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies
Arkenau, H.-T., Plummer, R., Molife, L.R., Olmos, D., Yap, T.A., Squires, M., Lewis, S., Lock, V., Yule, M., Lyons, J., Calvert, H., Judson, I.
Published in Annals of oncology (01.05.2012)
Published in Annals of oncology (01.05.2012)
Get full text
Journal Article
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
Molife, L R, Fong, P C, Paccagnella, L, Reid, A H M, Shaw, H M, Vidal, L, Arkenau, H-T, Karavasilis, V, Yap, T A, Olmos, D, Spicer, J, Postel-Vinay, S, Yin, D, Lipton, A, Demers, L, Leitzel, K, Gualberto, A, de Bono, J S
Published in British journal of cancer (27.07.2010)
Published in British journal of cancer (27.07.2010)
Get full text
Journal Article
Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
de Bono, J.S., Molife, L.R., Sonpavde, G., Maroto, J.P., Calvo, E., Cartwright, T.H., Loesch, D.M., Feit, K., Das, A., Zang, E.A., Wanders, J., Agoulnik, S., Petrylak, D.P.
Published in Annals of oncology (01.05.2012)
Published in Annals of oncology (01.05.2012)
Get full text
Journal Article
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
ATTARD, G, SARKER, D, REID, A, MOLIFE, R, PARKER, C, DE BONO, J. S
Published in British journal of cancer (09.10.2006)
Published in British journal of cancer (09.10.2006)
Get full text
Journal Article
Association of creatine kinase and skin toxicity in phase I trials of anticancer agents
Moreno Garcia, V, Thavasu, P, Blanco Codesido, M, Molife, L R, Vitfell Pedersen, J, Puglisi, M, Basu, B, Shah, K, Iqbal, J, de Bono, J S, Kaye, S B, Banerji, U
Published in British journal of cancer (20.11.2012)
Published in British journal of cancer (20.11.2012)
Get full text
Journal Article
Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)
Steele, N. L., Plumb, J. A., Vidal, L., Tjørnelund, J., Knoblauch, P., Buhl-Jensen, P., Molife, R., Brown, R., de Bono, J. S., Evans, T. R. J.
Published in Cancer chemotherapy and pharmacology (01.06.2011)
Published in Cancer chemotherapy and pharmacology (01.06.2011)
Get full text
Journal Article
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience
Molife, L.R., Alam, S., Olmos, D., Puglisi, M., Shah, K., Fehrmann, R., Trani, L., Tjokrowidjaja, A., de Bono, J.S., Banerji, U., Kaye, S.B.
Published in Annals of oncology (01.08.2012)
Published in Annals of oncology (01.08.2012)
Get full text
Journal Article
339 Clinical outcome and prognostic factors of patients (pts) with relapsed mesothelioma on phase I trials in the Drug Development Unit (DDU) of the Royal Marsden Hospital (RMH)
Papadatos-Pastos, D, Roda, D, Luken, M. De Miguel, Jalil, A, Diamantis, N, Michalarea, V, Lima, J, Capelan, M, Bodla, S, Bhosle, J, Molife, R, O'Brien, M, Banerji, U, Popat, S, Yap, T
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
Blagden, S P, Molife, L R, Seebaran, A, Payne, M, Reid, A H M, Protheroe, A S, Vasist, L S, Williams, D D, Bowen, C, Kathman, S J, Hodge, J P, Dar, M M, de Bono, J S, Middleton, M R
Published in British journal of cancer (11.03.2008)
Published in British journal of cancer (11.03.2008)
Get full text
Journal Article
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety
Matulonis, U.A., Penson, R.T., Domchek, S.M., Kaufman, B., Shapira-Frommer, R., Audeh, M.W., Kaye, S., Molife, L.R., Gelmon, K.A., Robertson, J.D., Mann, H., Ho, T.W., Coleman, R.L.
Published in Annals of oncology (01.06.2016)
Published in Annals of oncology (01.06.2016)
Get full text
Journal Article
Hyperglycemia and Phosphatidylinositol 3‐Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management
Khan, Khurum H., Wong, Mabel, Rihawi, Karim, Bodla, Shankar, Morganstein, Daniel, Banerji, Udai, Molife, Lulama R.
Published in The oncologist (Dayton, Ohio) (01.07.2016)
Published in The oncologist (Dayton, Ohio) (01.07.2016)
Get full text
Journal Article
1232 POSTER Creatinine Clearance (CrCI) as a Predictive Marker for the Risk of Toxicity From Molecularly Targeted Agents (MTA) in Phase I Trials
Vitfell-Pedersen, J, Basu, B, Moreno, V, Tjokrowidjaja, A, Puglisi, M, Shah, K, Malvankar, S, Alam, S, Molife, R, Banerji, U
Published in European journal of cancer (1990) (2011)
Published in European journal of cancer (1990) (2011)
Get full text
Journal Article
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours
Greystoke, A., Blagden, S., Thomas, A. L., Scott, E., Attard, G., Molife, R., Vidal, L., Pacey, S., Sarkar, D., Jenner, A., De-Bono, J. S., Steward, W.
Published in Annals of oncology (01.08.2006)
Published in Annals of oncology (01.08.2006)
Get full text
Journal Article
Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials
Basu, B., Vitfell-Pedersen, J., Moreno Garcia, V., Puglisi, M., Tjokrowidjaja, A., Shah, K., Malvankar, S., Anghan, B., de Bono, J.S., Kaye, S.B., Molife, L.R., Banerji, U.
Published in Oncology (01.08.2012)
Published in Oncology (01.08.2012)
Get full text
Journal Article